Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study
Background: Allergen immunotherapy (AIT) is the only causal treatment for respiratory allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the evidence from randomised controlled trials (RCTs). Methods: REACT (Real world effectiveness in allergy immunotherapy) is a retrospective cohort study using claims data between 2007 and 2017. Study eligibility was a confirmed diagnosis of allergic rhinitis (AR), with or without asthma, and AIT. To ensure comparable groups, AIT-treated subjects were propensity score matched 1:1 with control subjects, using characteristic and... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Allergy immunotherapy (AIT) / allergic rhinitis (AR) / allergy / asthma / effectiveness / follow-up (FU) / house dust mite (HDM) / health care resource utilisation (HRU) / inhaled corticosteroids (ICS) / intranasal corticosteroids (INCS) / long-acting beta2-agonists (LABA) / propensity score matching (PSM) / randomised clinical trial (RCT) / real world evidence (RWE) / retrospective cohort study / Rx prescription / short-acting beta2-agonists (SABA) / subcutaneous immunotherapy (SCIT) / sublingual immunotherapy (SLIT) |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26879223 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11392/2474403 |